Stocktoria
Cyclerion Therapeutics, Inc. CYCN
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2019-03-18
Cyclerion Therapeutics, Inc. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | -239.8% | -181.4% | — | -6242.4% | -1400.2% |
| Net margin | -170.1% | -152.8% | — | -14841.1% | -1310.2% |
| FCF margin | — | — | — | -13673.7% | -926.5% |
| Return on assets | -35.3% | -31.9% | -39.4% | -243.8% | -87.0% |
| Return on equity | -38.8% | -34.5% | -46.6% | -421.7% | -107.0% |
| Current ratio | 5.15 | 5.83 | 3.85 | 1.94 | 5.00 |
| Revenue growth | 3.7% | — | -100.0% | -92.5% | 71.7% |
Source: SEC EDGAR filings · CIK 0001755237 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.